|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
9,230,000 |
Market
Cap: |
3.60(M) |
Last
Volume: |
426,351 |
Avg
Vol: |
425,192 |
52
Week Range: |
$0.39 - $0.39 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company working to develop cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a Polo-Like-Kinase 1(PLK 1) inhibitor, in cancers. CDKs are a family of enzymes discovered as regulators of the cell cycle. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,956 |
7,956 |
7,956 |
Total Buy Value |
$0 |
$26,374 |
$26,374 |
$26,374 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
2 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sems Lloyd |
Director |
|
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
Henney Christopher S |
Director |
|
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
Spiegel Robert J. |
Director |
|
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
Dart Kenneth Bryan |
10% Owner |
|
2017-07-19 |
4 |
B |
$2.00 |
$1,700,000 |
D/D |
850,000 |
2,167,261 |
2.45 |
- |
|
Tang Capital Partners Lp |
10% Owner |
|
2017-02-23 |
4 |
B |
$4.34 |
$582,079 |
I/I |
134,200 |
559,900 |
1.5 |
- |
|
Tang Capital Partners Lp |
10% Owner |
|
2017-02-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
425,700 |
|
- |
|
Dart Kenneth Bryan |
10% Owner |
|
2015-03-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,607,143 |
|
- |
|
Chiao Judy |
V.P., Clin. Dev. & Reg. Aff. |
|
2014-12-06 |
5 |
D |
$2.99 |
$9,305 |
D/D |
(3,112) |
58,008 |
|
- |
|
Rombotis Spiro |
President & CEO |
|
2014-12-06 |
5 |
D |
$2.99 |
$11,634 |
D/D |
(3,891) |
237,525 |
|
- |
|
Barker Sam L |
Director |
|
2014-11-20 |
4 |
B |
$3.00 |
$9,300 |
D/D |
3,100 |
3,100 |
2.39 |
- |
|
Rombotis Spiro |
President & C.E.O. |
|
2013-05-21 |
4 |
B |
$3.00 |
$300,000 |
D/D |
100,000 |
241,416 |
2.81 |
- |
|
Rombotis Spiro |
President & C.E.O. |
|
2013-05-21 |
4 |
B |
$3.00 |
$300,000 |
D/D |
100,000 |
268,292 |
2.81 |
- |
|
Mcbarron Paul |
EVP, Finance, CFO, COO |
|
2013-05-21 |
4 |
B |
$3.00 |
$39,213 |
D/D |
12,948 |
70,096 |
2.81 |
- |
|
Sems Lloyd |
Director |
|
2013-05-21 |
4 |
B |
$3.00 |
$99,999 |
I/I |
33,333 |
33,333 |
2.1 |
- |
|
Chiao Judy |
V.P., Clin. Dev. & Reg. Aff. |
|
2013-01-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
25,668 |
39,024 |
|
- |
|
Rombotis Spiro |
President & CEO |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
30,791 |
157,501 |
|
- |
|
Mcbarron Paul |
EVP, Finance, CFO, COO |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
26,712 |
68,721 |
|
- |
|
Chiao Judy |
V.P., Clin. Dev. & Reg. Aff. |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,668 |
55,452 |
|
- |
|
Rombotis Spiro |
President & C.E.O. |
|
2011-12-23 |
4 |
B |
$0.50 |
$7,871 |
D/D |
15,902 |
746,516 |
2.81 |
- |
|
Rombotis Spiro |
President & C.E.O. |
|
2011-12-22 |
4 |
OE |
$0.44 |
$33,000 |
D/D |
75,000 |
730,614 |
|
- |
|
Rombotis Spiro |
President & C.E.O. |
|
2011-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
655,614 |
|
- |
|
Chiao Judy |
V.P., Clin. Dev. & reg. Aff. |
|
2011-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
133,168 |
|
- |
|
Sosnowski Robert Edward |
VP, Marketing & Sales |
|
2011-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
28,000 |
|
- |
|
Mcbarron Paul |
EVP, Finance, CFO, COO |
|
2011-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
263,054 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2011-09-23 |
4 |
S |
$0.51 |
$332,930 |
I/I |
(650,000) |
2,806,900 |
|
- |
|
281 Records found
|
|
Page 2 of 12 |
|
|